{"id":"https://openalex.org/W2474969466","doi":null,"title":"Synthesis of putative peroxisome proliferator-activated receptor \u03b4 antagonists","display_name":"Synthesis of putative peroxisome proliferator-activated receptor \u03b4 antagonists","alternate_titles":[],"publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2474969466","mag":"2474969466"},"language":"en","primary_location":{"id":"pmh:https://api.nva.unit.no/publication/019c8f5dfc0c-cf332cf5-b900-4ac0-a79a-e7c870d3b9d7","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10852/12045","pdf_url":null,"source":{"id":"https://openalex.org/S7407153562","display_name":"NVA (Nasjonalt vitenarkiv)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/masterThesis"},"parent_works":[],"lineage":["https://openalex.org/W2474969466"],"child_works_count":0,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://hdl.handle.net/10852/12045","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012403277","display_name":"Cecilie Xuan Trang Vo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184942183","display_name":"University of Oslo","ror":"https://ror.org/01xtthb56","country_code":"NO","type":"education","lineage":["https://openalex.org/I184942183"]}],"countries":["NO"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Cecilie Xuan Trang Vo","raw_affiliation_strings":["School of Pharmacy, Faculty of Mathematics and Natural Sciences, UNIVERSITY OF OSLO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, Faculty of Mathematics and Natural Sciences, UNIVERSITY OF OSLO","institution_ids":["https://openalex.org/I184942183"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5012403277"],"corresponding_institution_ids":["https://openalex.org/I184942183"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ppardelta","display_name":"PPAR\u03b4","score":0.9390000104904175},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.34299999475479126},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8289999961853027},{"id":"https://openalex.org/keywords/metabolic-syndrome","display_name":"metabolic syndrome","score":0.996999979019165},{"id":"https://openalex.org/keywords/reverse-cholesterol-transport","display_name":"reverse cholesterol transport","score":0.6800000071525574},{"id":"https://openalex.org/keywords/high-density-lipoprotein","display_name":"high-density lipoprotein","score":0.8840000033378601},{"id":"https://openalex.org/keywords/molecular-modeling","display_name":"molecular modeling","score":0.7269999980926514},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C187345961","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator-activated receptor","level":3,"score":0.6699190139770508},{"id":"https://openalex.org/C2910266098","wikidata":"https://www.wikidata.org/wiki/Q419629","display_name":"Peroxisome proliferator","level":4,"score":0.5256541967391968},{"id":"https://openalex.org/C127078168","wikidata":"https://www.wikidata.org/wiki/Q138639","display_name":"Peroxisome","level":3,"score":0.524504542350769},{"id":"https://openalex.org/C130241916","wikidata":"https://www.wikidata.org/wiki/Q20970208","display_name":"Peroxisome proliferator-activated receptor gamma","level":4,"score":0.46862107515335083},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4615499973297119},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4348514974117279},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.43435704708099365},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.29045426845550537},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.24484935402870178}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:https://api.nva.unit.no/publication/019c8f5dfc0c-cf332cf5-b900-4ac0-a79a-e7c870d3b9d7","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10852/12045","pdf_url":null,"source":{"id":"https://openalex.org/S7407153562","display_name":"NVA (Nasjonalt vitenarkiv)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/masterThesis"},{"id":"pmh:oai:www.duo.uio.no:10852/12045","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10852/12045","pdf_url":null,"source":{"id":"https://openalex.org/S7407064446","display_name":"NORA - Norwegian Open Research Archives","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/masterThesis"},{"id":"mag:2474969466","doi":null,"is_oa":false,"landing_page_url":"https://www.duo.uio.no/bitstream/10852/12045/4/Masteroppgave_Vo_Cecilie.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"pmh:https://api.nva.unit.no/publication/019c8f5dfc0c-cf332cf5-b900-4ac0-a79a-e7c870d3b9d7","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10852/12045","pdf_url":null,"source":{"id":"https://openalex.org/S7407153562","display_name":"NVA (Nasjonalt vitenarkiv)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/masterThesis"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320323260","display_name":"Universitetet i Oslo","ror":"https://ror.org/01xtthb56"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2474969466.pdf","grobid_xml":"https://content.openalex.org/works/W2474969466.grobid-xml"},"referenced_works_count":38,"referenced_works":["https://openalex.org/W68945099","https://openalex.org/W1566184524","https://openalex.org/W1964906652","https://openalex.org/W1965881474","https://openalex.org/W1975138199","https://openalex.org/W1975537939","https://openalex.org/W1977666051","https://openalex.org/W1982027543","https://openalex.org/W1983519362","https://openalex.org/W1987601141","https://openalex.org/W1991113982","https://openalex.org/W1996523196","https://openalex.org/W2001662680","https://openalex.org/W2008404887","https://openalex.org/W2030330182","https://openalex.org/W2031581878","https://openalex.org/W2034131665","https://openalex.org/W2034618205","https://openalex.org/W2043648447","https://openalex.org/W2045792069","https://openalex.org/W2052247385","https://openalex.org/W2063175340","https://openalex.org/W2063464658","https://openalex.org/W2075783070","https://openalex.org/W2088562758","https://openalex.org/W2097105383","https://openalex.org/W2097205737","https://openalex.org/W2101371764","https://openalex.org/W2115088156","https://openalex.org/W2120822075","https://openalex.org/W2126218858","https://openalex.org/W2128557965","https://openalex.org/W2132741387","https://openalex.org/W2158324747","https://openalex.org/W2167896406","https://openalex.org/W2498399983","https://openalex.org/W2951737696","https://openalex.org/W3063220799"],"related_works":["https://openalex.org/W2396508521","https://openalex.org/W2043091080","https://openalex.org/W1988717738","https://openalex.org/W2035514794","https://openalex.org/W7034346476","https://openalex.org/W2898106106","https://openalex.org/W2097205737","https://openalex.org/W1994819141","https://openalex.org/W2253202143","https://openalex.org/W2092782010"],"abstract_inverted_index":{"During":[0],"the":[1,19,22,42,74,81,94,104,114,134,154,157,168,172],"last":[2],"decade,":[3],"peroxisome":[4],"proliferator-activated":[5],"receptor":[6],"\u03b4":[7],"(PPAR\u03b4)":[8],"has":[9],"received":[10],"great":[11],"attention":[12],"as":[13,52,54,133],"a":[14,55,129,145],"potential":[15],"drug":[16],"target":[17],"for":[18,153],"prevention":[20],"of":[21,33,44,84,90,96,107,116,156,171],"metabolic":[23],"syndrome":[24],"and":[25,39,48,66],"type":[26],"2":[27],"diabetes.":[28],"The":[29,137],"beneficial":[30,82],"biological":[31,105],"effects":[32,83,95],"PPAR\u03b4":[34,85,97,119,131],"activation":[35],"are":[36,70,177],"well":[37,53],"established,":[38],"increases":[40],"in":[41,57,99],"amount":[43],"high-density":[45],"lipoprotein":[46],"(HDL)":[47],"reverse":[49],"cholesterol":[50],"transport,":[51],"decrease":[56],"plasma":[58],"glucose.":[59],"However,":[60],"much":[61],"remains":[62],"to":[63,67,80,92,101],"be":[64],"discovered,":[65],"date,":[68],"there":[69],"no":[71],"drugs":[72],"on":[73,113],"market":[75],"targeting":[76],"this":[77],"receptor.":[78],"Due":[79],"activation,":[86],"it":[87],"is":[88,167],"also":[89],"interest":[91],"investigate":[93],"antagonism,":[98],"order":[100],"further":[102],"elucidate":[103],"role":[106],"PPAR\u03b4.":[108],"This":[109],"thesis":[110],"therefore":[111],"focused":[112],"development":[115],"new":[117],"high-affinity":[118],"antagonists.":[120],"In":[121],"total,":[122],"eleven":[123],"compounds":[124],"were":[125,141],"prepared":[126],"using":[127],"GSK3787,":[128],"selective":[130],"antagonist,":[132],"lead":[135],"compound.":[136],"first-generation":[138],"analogues,":[139],"7-16,":[140],"synthesized":[142,173],"partly":[143],"by":[144],"published":[146],"route.":[147],"An":[148],"efficient":[149],"approach":[150],"was":[151],"developed":[152],"synthesis":[155],"second-generation":[158],"analogue":[159],"23.":[160],"Molecular":[161],"modelling":[162],"studies":[163,176],"indicate":[164],"that":[165],"23":[166],"most":[169],"potent":[170],"compounds.":[174],"Biological":[175],"currently":[178],"ongoing.":[179]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2474969466","counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-07-22T00:00:00"}
